Citi Sees Gilead As A $156 Stock -- It Was At... ~$130 Yesterday -- Now, $140 As Of This Morning. Go Get Some!

Back to the more mundane aspects of our power alley, here. [Disclosure: I've been long this name for four years -- since about ~$80/share.]

But this is still a very nice one year upside -- if you happen to catch a day where it is trading around say $130. . . here's the auto-genned data:

. . .Gilead Sciences had its target price upped by investment analysts at Citigroup from $140.00 to $156.00 in a research report issued on Tuesday. . . . The firm currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's target price suggests a potential upside of 11.63% from the stock's previous close.

The name had been the topic of several other recent positive research reports. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 10th. . . .

Now you know. This is an immensely solid, and well-run bio/pharma company. Trust that.

नमस्ते